Eu HIV & Hep Abstracts 2022_56

European Meeting on HIV & Hepatitis 2022

Prevalence and viral load suppression rate among children and adolescents with dual infections (any two of HIV, HBV, and HCV) in Nnewi, Nigeria

European Meeting on HIV & Hepatitis 2022

Proviral DNA for detection of HIV-1 subtype A drug resistance mutations

European Meeting on HIV & Hepatitis 2022

Combined COVID-19 vaccination and hepatitis C virus screening intervention for high-risk populations at a centre for addiction services in Barcelona, Spain

European Meeting on HIV & Hepatitis 2022

Combined COVID-19 vaccination and hepatitis C virus and HIV screening intervention for high- risk populations at a mobile testing unit in Madrid, Spain

European Meeting on HIV & Hepatitis 2022

Community perspectives on self- testing for HIV and HCV in the WHO European region

European Meeting on HIV & Hepatitis 2022

Viral load suppression after three-year Ibalizumab treatment in a multidrug-resistant HIV-1- infected woman: Clinical experience.

European Meeting on HIV & Hepatitis 2022

CASE - HIV+ End-Stage Renal Disease Patient with Immunosuppressive Drug-Drug Interactions Received Successful Transplantation after Ibalizumab Suppressed Switch

European Meeting on HIV & Hepatitis 2022

Clinical course of AIDS with COVID-19 coinfection with prolonged SARS CoV-2 replication despite remdesivir/molnupiravir treatment.

European Meeting on HIV & Hepatitis 2022

A Case of IRIS Syphilis Due to Prozone Effect

European Meeting on HIV & Hepatitis 2022

Update on COVID-19 Therapeutics (May 2022 Edition) | Daniel Kuritzkes, MD

COVID-19 Clinical Forum 2022

Update on COVID-19 Therapeutics (May 2022 Edition) - Daniel Kuritzkes, MD

COVID-19 Clinical Forum 2022

Case-Based Discussion of Oral Antivirals for COVID-19: Learning from Experience – Part 2 | Fiona Marra, MPharm, MSc

Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

Case-Based Discussion of Oral Antivirals for COVID-19: Learning from Experience - Part 1 | Catia Marzolini, PharmD, PhD

Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

Oral Antivirals for COVID-19: Drug-Drug Interactions as a Manageable Risk | David Burger, PharmD, PhD

Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

Oral Antivirals for COVID-19: How to Best Make Use of Their Therapeutic Effects | Giovanni Di Perri, MD, PhD

Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

Case-Based Discussion of Oral Antivirals for COVID-19: Learning from Experience – Part 2 - Fiona Marra, MPharm, MSc

Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

Case-Based Discussion of Oral Antivirals for COVID-19: Learning from Experience - Part 1 - Catia Marzolini, PharmD, PhD

Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

Oral Antivirals for COVID-19: Drug-Drug Interactions as a Manageable Risk - David Burger, PharmD, PhD

Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

Oral Antivirals for COVID-19: How to Best Make Use of Their Therapeutic Effects - Giovanni Di Perri, MD, PhD

Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

COVID-19 Vaccines - State of the Art - Kathryn Stephenson, MD, MPH

International Workshop on COVID-19 Vaccines 2022 - June Edition

Immune Correlates of Protection from SARS-CoV-2 Infection - Miles Davenport, MB BS, DPhil

International Workshop on COVID-19 Vaccines 2022 - June Edition

Infection Induced and Hybrid Immunity - Jefferson Jones

International Workshop on COVID-19 Vaccines 2022 - June Edition

COVID-19 Vaccination in Pregnant and Lactating Individuals - A. Collier, MD

International Workshop on COVID-19 Vaccines 2022 - June Edition